Katelyn M Willis

USPTO Granted Patents = 12 (Patent Applications = 12)

EPO Patents = 2 (Patent Applications = 13)

Average Co-Inventor Count = 6.4

ph-index = 2

Forward Citations = 10(Granted Patents)

Location History:

La Jolla, CA (US) (2018 - 2024)
San Diego, CA (US) (2024)

Company Filing History:

Inhibrx Biosciences, Inc.

Years Active: 2018-2025

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12365728 - DLL3 single domain antibodies and therapeutic compositions thereof (2025-07-22),

2. 12331132 - Multispecific polypeptide constructs having constrained CD3 binding and related methods and uses (2025-06-17),

3. 12331126 - OX40-binding polypeptides and uses thereof (2025-06-17),

4. 12195533 - Multispecific polypeptide constructs containing a constrained CD3 binding domain and a receptor binding region and methods of using the same (2025-01-14),

5. 12012459 - OX40-binding polypeptides and uses thereof (2024-06-18),

6. 11976126 - Multivalent and multispecific DR5-binding fusion proteins and methods of modulating immune cells (2024-05-07),

7. 11866507 - Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same (2024-01-09),

8. 11447556 - OX40-binding polypeptides and uses thereof (2022-09-20),

9. 11117973 - Multivalent and multispecific DR5-binding fusion proteins and methods of treating neoplasms (2021-09-14),

10. 10844129 - Multivalent and multispecific glucocorticoid-induced TNFR-related protein (GITR)-binding single-domain antibody fusion proteins and encoding nucleic acids (2020-11-24),

11. 10308720 - Multivalent and multispecific DR5-binding fusion proteins (2019-06-04),

12. 10093742 - Multispecific GITR-binding fusion proteins and methods of use thereof (2018-10-09),

Title: **Innovative Contributions of Katelyn M Willis in Biomedicine**

Introduction

Katelyn M Willis, based in La Jolla, California, is an accomplished inventor with a remarkable portfolio of 8 patents. Her work focuses primarily on advancements in immunology and therapeutic development, showcasing her significant contributions to biomedical research.

Latest Patents

Among her latest patents is a groundbreaking creation involving OX40-binding polypeptides. This innovation includes VHH-containing polypeptides designed to bind to OX40, some of which also agonize the receptor. Furthermore, she has developed multivalent and multispecific DR5-binding fusion proteins. These proteins are intended to engage death receptor 5 (DR5), a part of the TNF receptor superfamily, offering new methods to modulate immune cell behavior.

Career Highlights

Katelyn has been instrumental in her roles at various prestigious companies. She has contributed her expertise at Inhibrx, Inc. and Inhibex, Inc., where she focused on developing innovative therapies utilizing her extensive knowledge in immunology and protein engineering. Her patents reflect her dedication to advancing medical science and addressing unmet healthcare needs.

Collaborations

Throughout her career, Katelyn has collaborated with notable professionals, including John C Timmer and Brendan P Eckelman. These collaborations have fostered an environment of innovation and have been crucial in advancing her research endeavors.

Conclusion

Katelyn M Willis stands out as a prominent inventor in the field of biomedicine. Her significant patent portfolio and collaborative efforts demonstrate her commitment to innovation and her impact on the future of therapeutic development. As her career progresses, she is likely to continue making influential contributions to science and healthcare.

This text is generated by artificial intelligence and may not be accurate.